A Phase I Study Of Etrolizumab Followed By Open-Label Extension And Safety Monitoring In Pediatric Patients With Moderate To Severe Ulcerative Colitis Or Moderate To Severe Crohn's Disease

• Status: Active, not recruiting
• Trial end date: 2027-12-18
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hoffmann-La Roche
• Treatments: Etrolizumab

Criteria

Inclusion Criteria:

• Age of 4 years to <18 years at the time of signing the Informed Consent Form.

• Weight of 13 kilograms (kg) or more

• Diagnosis of ulcerative colitis (UC) or Crohn's Disease (CD) confirmed by biopsy and established for ≥3 months (i.e., after first diagnosis by a physician according to American College of Gastroenterology [ACG] guidelines) prior to screening

• Inadequate response, loss of response or intolerance to prior immunosuppressants and/or corticosteroid treatment and/or anti-tumor necrosis factor (TNF) therapy

• For postpubertal females of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use acceptable contraceptive methods during the treatment period and for at least 24 weeks after the last dose of etrolizumab.

• For male patients: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm

Exclusion Criteria:

• Pregnant or lactating

• Lack of peripheral venous access

• Congenital or acquired immune deficiency

• Neurological conditions or diseases that may interfere with monitoring for progressive multifocal leukoencephalopathy (PML)

• History of demyelinating disease

• History of cancer, including hematologic malignancy, solid tumors, and carcinoma in situ, within 5 years before screening

Exclusion Criteria Related to Inflammatory Bowel Disease:

• Prior extensive colonic resection, subtotal or total colectomy, or planned surgery

• Past or present ileostomy or colostomy

• Diagnosis of indeterminate colitis

• Suspicion of ischemic colitis, radiation colitis, or microscopic colitis

• Diagnosis of toxic megacolon within 12 months of initial screening visit

• Abdominal abscess

• A history or current evidence of colonic mucosal dysplasia

• Patients with fixed symptomatic stenosis of the intestine

• Patients with history or evidence of adenomatous colonic polyps that have not been removed

Exclusion Criteria Related to Ulcerative Colitis:

• Severe extensive colitis per investigator judgment that colectomy is imminent

Exclusion Criteria Related to Crohn's Disease:

• Sinus tract with evidence for infection (e.g., purulent discharge) in the clinical judgment of the investigator

• Short-bowel syndrome

• Evidence of abdominal or perianal abscess

• Expected to require surgery to manage CD-related complications during the study

Exclusion Criteria Related to Prior or Concomitant Therapy:

• Any prior treatment with anti-integrin agents (including natalizumab, vedolizumab, and efalizumab), ustekinumab, anti-adhesion molecules (e.g., anti-MAdCAM-1), or rituximab

• Use of IV steroids within 30 days prior to screening with the exception of a single administration of IV steroid

• Use of agents that deplete B or T cells (e.g., alemtuzumab or visilizumab) within 12 months prior to Day 1, with the exception of AZA and 6-MP

• Use of cyclosporine, tacrolimus, sirolimus, or mycophenolate mofetil (MMF) within 4 weeks prior to Day 1

• Use of other biologics (e.g. anti-TNF) within 8 weeks before dosing (unless drug level is below detectability before completion of the 8-week interval)

• Chronic nonsteroidal anti-inflammatory drug (NSAID) use

• Patients who are currently using anticoagulants

• Apheresis (i.e., Adacolumn apheresis) within 2 weeks prior to Day 1

• Received any investigational treatment including investigational vaccines within 12 weeks prior to Day 1 of the study or 5 half-lives of the investigational product, whichever is greater

• History of moderate or severe allergic or anaphylactic/anaphylactoid reactions to chimeric, human, or humanized antibodies, fusion proteins, or murine proteins or hypersensitivity to etrolizumab (active drug substance) or any of the excipients (L-histidine, L-arginine, succinic acid, polysorbate 20)